Stay updated on HOPE-B: AMT-061 Clinical Trial

Sign up to get notified when there's something new on the HOPE-B: AMT-061 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HOPE-B: AMT-061 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Added new data points and definitions for outcomes and safety, including Month 60 AFP levels, inflammatory markers, anti-AAV5 antibodies, vector DNA shedding, adverse events, and multiple FIX activity and bleeding endpoints with specified timepoints. Deleted older endpoints and measurement definitions (for example ABR calculation method, lead-in FIX consumption and activity metrics, and some lead-in/18-month timepoints) to align with updated study reporting.
    Difference
    3%
    Check dated 2026-03-29T03:56:15.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Updated the site revision from v3.4.3 to v3.5.0; the page content and user workflows remain unchanged.
    Difference
    0.0%
    Check dated 2026-03-21T20:25:52.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing Revision: v3.4.2. The update does not modify study information, eligibility criteria, or results.
    Difference
    0.0%
    Check dated 2026-03-07T13:07:43.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The footer now displays Revision: v3.4.2, replacing Revision: v3.4.1. This appears to be a minor system update with no impact on study content or user actions.
    Difference
    0.0%
    Check dated 2026-02-13T17:23:42.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Publications section updated: added the NEJM article 'Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B' (N Engl J Med, 2026 Jan 29; DOI 10.1056/NEJMoa2514332) and removed the NEJM article 'Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B' (Dec 7, 2025).
    Difference
    0.1%
    Check dated 2026-02-06T11:16:33.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    Added UI toggles for glossary (Show glossary, Hide glossary). Updated metadata: Last Update Submitted that Met QC Criteria and No FEAR Act Data appear with revision to v3.4.0; older wording Last Update Submitted that met QC Criteria and No FEAR Act data were removed.
    Difference
    0.2%
    Check dated 2026-01-23T02:57:03.000Z thumbnail image

Stay in the know with updates to HOPE-B: AMT-061 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HOPE-B: AMT-061 Clinical Trial page.